Gate News message, April 23 — Xinyang (SY.US) and Jinbo Biotech (920982.BJ) announced a strategic partnership on April 22, with Jinbo’s new collagen product Weiyi Beauty ColPact being exclusively supplied to Xinyang Youth Clinic. Xinyang launched “Miracle Collagen” based on this product for facial and scalp anti-aging, priced at 1,999 yuan per unit or 2,999 yuan for two units.
China’s collagen market is rapidly expanding, with 18 Class III medical device registration certificates now approved as of April 2026. According to industry data, the market for recombinant collagen products has grown significantly, with market penetration reaching 56.9% in 2025. The Chinese medical aesthetics collagen injection market reached approximately 6.7 billion yuan in 2024, with a compound annual growth rate of 21.9% from 2021 to 2024. Recombinant collagen products alone are projected to reach 58.6 billion yuan by 2025, with forecasts suggesting the market will exceed 100 billion yuan by 2027.
Jinbo Biotech’s chairman Yang Xia noted that the company’s collagen products were initially priced around 6,900 yuan due to production capacity constraints of only 300 liters. The company has since expanded capacity to 3 tons and plans further expansion to 5 tons. Yang stated that at 5-ton capacity, the price will approach production cost and will not decrease further, as companies must maintain profit margins for continued research and development. Regarding price competition concerns, Xinyang CEO Jin Xing stated that prices are ultimately determined by supply and demand dynamics, and as more products enter the market, a tiered pricing structure—high-end (over 10,000 yuan), mid-range (4,000-6,000 yuan), and budget (500-2,000 yuan)—will emerge to serve diverse consumer needs and expand market penetration.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
Related Articles
TradFi Fall Alert: AKESO (AKESO 09926.HK) Falls Over 6%
Gate News: According to the latest Gate TradFi data, AKESO (AKESO 09926.HK) has dropped by 6% in a short period. Current volatility is significantly higher than recent averages, indicating increased market
GateNews6m ago
Nvidia H200 Shipments to China Delayed Over Approval, Terms Disagreements
US Commerce Secretary Howard Lutnick stated on April 22 that Nvidia has not sold its H200 AI chips to Chinese customers, citing lack of Beijing approval and China's prioritization of investment in domestic suppliers, according to Reuters.
The Trump administration cleared some China-bound H200
CryptoFrontier6m ago
Robinhood Invests $75M in OpenAI via New Venture Fund
Robinhood, a US trading platform, announced on April 22 that its venture fund invested $75 million in OpenAI as it seeks to provide retail investors access to private technology companies, according to Reuters. The investment comes as OpenAI has attracted strong investor interest amid a rush by
CryptoFrontier28m ago
Tesla Q1 2026 Battery Deployments Fall 15% YoY
Tesla’s lucrative energy storage unit, offsetting waning vehicle sales, fell 15% in Q1 2026 deployments; demand hinges on project timing, solar/wind trends, and AI data-center storage, with capex over $20B heightening cash-flow risk.
Abstract: This article analyzes Tesla's energy storage business, showing it as a higher-margin counterweight to a slipping vehicle division. It notes a 15% drop in first-quarter 2026 deployments, explores potential causes such as project timing and market slowdowns, and highlights growth in Megapack and data-center storage. Revenue has risen markedly from 2021 to 2025, and the unit funds capital expenditure, with expected 2026 capex above $20 billion. The piece discusses market headwinds from slower U.S. solar/wind development and the volatility of energy results, described as 'lumpy' due to project timing, and assesses implications for Tesla's cash flow.
CryptoFrontier40m ago
Keppel Q1 Profit Dips as Real Estate Segment Weakens; Iran War Impact Limited So Far
Gate News message, April 23 — Keppel reported a slight decline in first-quarter net profit on April 23, with lower contributions from its real estate division offset partially by stronger results from infrastructure and connectivity segments. The company flagged limited direct exposure to the
GateNews40m ago
TSMC ADR hits a record high, delays the introduction of ASML’s high-end equipment to control costs
TSMC ADR (U.S. stock ticker: TSM) surged more than 5% yesterday, closing at a record high of $387.44. Using a new Taiwan dollar exchange rate of 31.49, the implied price for Taiwan stock 2330 should be 2,440 yuan. As capital expenditures continue to expand, TSMC will delay the introduction of ASML High-NA EUV equipment. The R&D team has successfully unlocked additional potential on top of existing equipment and continues to advance the process roadmap.
TSM sets a new record high as foreign investors widely raise target prices
Recently, TSMC has benefited from the rapid growth in the AI chip application market, with its ADR share price hitting a new high. Several foreign brokerage firms also raised their target prices based on their financial forecasts. Among them, Barclays raised its target price from $450 to $470.
TSMC ADR closed yesterday at a record high of $387.44
ChainNewsAbmedia58m ago
